Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY   US02043Q1076

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/16/2015 01/20/2015 01/21/2015 01/22/2015 01/23/2015 Date
100.77(c) 96.25(c) 87.36(c) 93.17(c) 93.42(c) Last
512 705 783 387 5 035 536 2 415 870 698 689 Volume
+2.16% -4.49% -9.24% +6.65% +0.27% Change
More quotes
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which develops novel therapeutics based on RNA interference.It is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 42,0 M
EBIT 2014 -375 M
Net income 2014 -365 M
Finance 2014 486 M
Yield 2014 -
Sales 2015 49,2 M
EBIT 2015 -207 M
Net income 2015 -204 M
Finance 2015 568 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 172x
EV / Sales 2015 145x
Capitalization 7 715 M
More Financials
Latest news on ALNYLAM PHARMACEUTICALS, I
01/23 ISIS PHARMACEUTICALS : Alnylam and Isis Form New Agreement, Extending Decade-Lon..
01/20 ALNYLAM PHARMACEUTICALS : Prices Public Offering of Common Stock
01/20 ALNYLAM PHARMACEUTICALS : Announces Proposed Public Offering of $450 Million of ..
01/14 ALNYLAM PHARMACEUTICALS : Entry into a Material Definitive Agreement (form 8-K)
01/14 ALNYLAM PHARMACEUTICALS : Releases Data on Hemophilia Phenotype in Phase 1 Study
01/12 ISIS PHARMACEUTICALS : Alnylam, Isis form new agreement in RNA Therapeutics
01/11 ALNYLAM PHARMACEUTICALS : Pharma Announces Updated Results From Phase 1 Study Of..
01/11 ALNYLAM PHARMACEUTICALS : Read more
More news
Sector news Biotechnology & Medical Research - NEC
01/23 INCYTE : Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Ap..
01/23 MEDIVATION : Astellas -enzalutamide phase 2 terrain trial demonstrated statistic..
01/22 QUINTILES TRANSNATIONAL : Investigator Initiated Trials is Topic of New Handbook..
Plus d'actualités du secteur Biotechnology & Medical Research - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF